ACRGF:OTC-Acreage Holdings, Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | OTC

Last Closing Price

USD 2.65

Change

0.00 (0.00)%

Market Cap

USD 0.27B

Volume

0.27M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


Acreage Holdings, Inc (ACRGF) Stock Analysis:
Based on the Acreage Holdings, Inc stock forecasts from 0 analysts, the average analyst target price for Acreage Holdings, Inc is not available over the next 12 months. Acreage Holdings, Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Acreage Holdings, Inc is Very Bearish, which is based on 0 positive signals and 1 negative signals. At the last closing, Acreage Holdings, Inc’s stock price was USD 2.65. Acreage Holdings, Inc’s stock price has changed by +0.00% over the past week, +0.00% over the past month and +0.00% over the last year.

About

Acreage Holdings, Inc., formerly High Street Capital Partners, is a principal investment firm specializing in cannabis industry. Acreage Holdings, Inc. was founded in 2014 and is based in New York, New York.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-19 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MKKGY MERCK Kommanditgesellschaft au..

N/A

USD95.21B 31.01 21.63
MKGAF MERCK Kommanditgesellschaft au..

-1.44 (-0.66%)

USD95.21B 30.87 21.63
TKPHF Takeda Pharmaceutical Company ..

-0.72 (-2.42%)

USD46.58B 11.33 0.06
SGIOY Shionogi & Co. Ltd

N/A

USD19.93B 19.84 0.12
SGIOF Shionogi & Co. Ltd

-2.03 (-3.13%)

USD19.61B 19.58 0.12
SFOSF Shanghai Fosun Pharmaceutical ..

N/A

USD18.36B 15.49 3.03
ESALY Eisai Co. Ltd

-0.39 (-0.74%)

USD15.57B 28.18 0.13
ESALF Eisai Co. Ltd

N/A

USD15.43B 28.29 0.13
GNHAF Vifor Pharma AG

N/A

USD11.43B 24.38 12.99
MTZPY Mitsubishi Tanabe Pharma Corpo..

N/A

USD10.43B 79.00 0.21

ETFs Containing ACRGF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -29.58% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -29.58% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 33.96% N/A N/A N/A N/A
Risk Adjusted Return -87.11% N/A N/A N/A N/A
Market Capitalization 0.27B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 0.99 N/A N/A N/A N/A
Price / Cash Flow Ratio -3.85 N/A N/A N/A N/A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -86.41% N/A N/A N/A N/A
Return on Invested Capital -43.10% N/A N/A N/A N/A
Return on Assets -19.19% N/A N/A N/A N/A
Debt to Equity Ratio 6.94% N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 258.06 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.